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Abstract
Chikungunya virus is a mosquito-borne alphavirus that causes fever and
debilitating joint pains in humans. Joint pains may last months or years. It is
vectored primarily by the tropical and sub-tropical mosquito, , but Aedes aegypti
is also found to be transmitted by , a mosquito species thatAedes albopictus
can also be found in more temperate climates. In recent years, the virus has
risen from relative obscurity to become a global public health menace affecting
millions of persons throughout the tropical and sub-tropical world and, as such,
has also become a frequent cause of travel-associated febrile illness. In this
review, we discuss our current understanding of the biological and sociological
underpinnings of its emergence and its future global outlook.
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Introduction
As with several other mosquito-borne alphaviruses, chikungunya 
virus causes a fever-rash-arthralgia syndrome in humans. The 
name chikungunya derives from the debilitating joint pain noted 
by local populations during an outbreak in 1952–53 in what is now 
Tanzania. The local word “chikungunya”, meaning “that which 
bends up” was given as a result of the stooped posture that resulted 
from the pain of the disease1,2. The arthralgia can persist for months 
or even years in some affected persons and can progress to frank 
arthritis in some3–15. Symptoms typically occur in 72–97% of 
those infected15–19, but one study, in an area where the virus has 
been long established endemically, showed that only 18% of 
infections resulted in clinical illness, possibly due to re-exposure 
events that did not result in clinical illness20. Since 2004, massive 
urban outbreaks producing considerable morbidity in a widening 
geographical area have occurred throughout the topical and sub- 
tropical world. In this review, we will explore the complex interplay 
of entomological, virological, and sociological factors contributing 
to its emergence, speculate on future epidemiological trends, and 
outline the possibilities for control.
Transmission cycles and mosquito vectors
Three chikungunya viral genotypes are recognized, which histori-
cally have circulated in the distinct geographical regions for which 
they are named: West African genotype, East Central South African 
(ECSA) genotype, and Asian genotype21. Phylogenetic evidence 
suggests that the Asian genotype virus derived from the ECSA 
virus sometime between 1879 and 192722. In Africa, the virus is 
maintained in a sylvatic cycle involving non-human primates and 
forest-dwelling Aedes spp. mosquitoes23. In these rural regions, 
human outbreaks tend to be small and dependent on environmental 
conditions (such as increased rainfall) that increase sylvatic mos-
quito densities, particularly of the Aedes furcifer-tayleri group23,24. 
A sylvatic transmission cycle has not been identified in Asia, but is 
likely present due to ongoing, low level, human activity.
Like the arthropod-borne viruses (arboviruses) dengue, yellow 
fever, o’nyong’nyong, and Zika, humans are not dead-end hosts for 
chikungunya virus but rather serve as part of the transmission cycle 
by efficiently infecting Aedes aegypti mosquitoes. This property 
enables rapid human-mosquito-human transmission cycles in urban 
areas, which can produce massive outbreaks. Aedes aegypti is a 
highly efficient urban vector because it preferentially bites humans 
and often bites multiple humans in the course of acquiring a com-
plete, single blood meal. Furthermore, Aedes aegypti breeds in the 
ubiquitous small pools of water found around human habitation, 
often bringing the vectors in close proximity to human hosts facili-
tating further transmission25,26.
In addition to Aedes aegypti, other mosquito vectors must be 
considered. Of particular interest is Aedes albopictus (Asian 
tiger mosquito), an aggressive, human-biting mosquito that has 
spread globally from its native Asia largely from international 
trade in used tires and other commodities in recent years27,28. 
Unlike Aedes aegypti, which exists in tropical and subtropi-
cal areas, Aedes albopictus can also thrive in temperate regions, 
thus potentially introducing chikungunya virus to new ecological 
niches29,30. Furthermore, other members of the Stegomyia subgenus 
may be important under certain circumstances. Aedes henselli 
was the principal vector of a large outbreak on Yap Island in 
Micronesia31,32. Other species present in focal areas may be of local 
importance.
Early outbreaks
Although chikungunya virus cannot be definitively linked to out-
breaks before its discovery in the mid-1950s, outbreaks of fever and 
debilitating polyarthralgia affecting a substantial proportion of the 
affected population were noted in many areas during the 18th and 19th 
centuries, including Africa, Asia, India, the West Indies, Indonesia, 
and the southern United States33,34. Interestingly, contemporary 
physicians called this disease “dengue” and noted its clinical simi-
larities as well as its differences between what is currently known 
as “dengue” and “breakbone fever”. In the mid-1950s, several 
authors (including Sabin)35 isolated the “breakbone fever” viruses 
and called them “dengue viruses”, and the former “dengue” became 
“chikungunya” following the 1952–53 outbreak that produced the 
first isolation of chikungunya virus. While some of these previous 
historical outbreaks could have been due to chikungunya virus, they 
also could have been caused by other viruses already present in 
specific locations and causing the same clinical syndrome, such as 
Mayaro virus in the Americas or o’nyong’nyong virus in Africa.
Following the discovery of chikungunya virus, numerous small 
outbreaks were noted in Africa. However, massive outbreaks were 
noted in Thailand in the late 1950s and early 1960s36,37, and in India 
from the early 1960s into the 1970s38. Approximately 31% of the 
population of Bangkok became infected during the 1962 outbreak36. 
Antibody prevalence ranged from 10–20% of the 1–2 year olds to 
70–85% among adults, suggesting long-standing endemicity in 
that area. High attack rates were noted during outbreaks in Madras 
(40%) in 1962–64 and in Barsi (37%) in 197339. For unknown 




The current epidemic, ongoing since 2004, involves many tropi-
cal and sub-tropical areas of Africa, Asia, Europe, the Pacific 
archipelago, and the Americas. Both ECSA and Asian genotype 
viruses, sometimes together, are responsible for epidemics, depend-
ing on location. The fact that both genotypes have nearly simultane-
ously re-emerged after years of relatively little activity suggests that 
similar forces may be driving their re-emergence. This hypothesis 
is reinforced by our recent experience of substantial geographical 
spread and massive increased disease incidence of the four dengue 
serotype viruses which, as noted earlier, are vectored also by Aedes 
aegypti mosquitoes in human-mosquito-human urban transmission 
cycles41. Factors attributed to dengue emergence include increased 
human travel, urbanization of human populations, uncontrolled 
urban growth (leading to increases in Aedes aegypti breeding sites), 
and lack of adequate control measures42,43. While dengue incidence 
in the Americas has been increasing for more than three decades, 
large increases have occurred in the last decade, suggesting an epi-
demiological turning point highly permissive for the transmission 
and spread of Aedes aegypti-vectored arboviruses. This point was 
recently reinforced by the spread throughout the Pacific44,45 and into 
the Americas (Brazil)46,47 for the first time of Zika virus, a flavivirus 
also spread from human to human via Aedes aegypti.
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Re-emergence of the ECSA genotype
As mentioned previously, chikungunya outbreaks now occurring 
globally are caused by both ECSA and Asian genotypes. The cur-
rent ECSA outbreak began on Lamu Island on coastal Kenya in 
200411. This outbreak involved an estimated 13,500 persons, which 
was quite substantial compared to other contemporary African 
chikungunya outbreaks. Eight months later on Comoros, an island 
off the coast of Tanzania, an outbreak involved nearly 215,000 
of that island’s residents48. Phylogenetic analysis showed that the 
causative ECSA genotype virus was nearly genetically identical to 
the Lamu Island outbreak, suggesting that the Comoros outbreak 
was simply an extension of the Lamu Island outbreak49. A small 
outbreak on La Reunion Island also began in 2005, an island with 
very low Aedes aegypti populations. Atypical of recent chikungunya 
outbreaks, this outbreak smouldered until December 2005 when 
incidence dramatically increased, eventually involving >244,000 
persons50. Viral isolates collected in 2006 contained an envelope 
protein mutation (E1: A226V) that was found to increase viral fit-
ness in Aedes albopictus mosquitoes51,52, which led to the hypoth-
esis that the lack of abundant Aedes aegypti populations produced 
the outbreak’s slow onset, but incidence picked up when the viral 
mutation increased transmission efficiency for the abundant Aedes 
albopictus mosquito.
The ECSA virus containing the E1: A226V mutation subsequently 
spread from La Reunion Island to India by 2006, where over 
1 million cases were reported in the first year alone53. Activity in 
India still continues nearly a decade later. From India, the Indian 
Ocean lineage strain spread to Southeast Asia and to northern 
Italy17,54. The Italian outbreak, which involved approximately 300 
persons, was significant as this was the first outbreak documented 
in a subtropical climate in an area where the only vector species was 
Aedes albopictus.
Autochthonous transmission of an ECSA genotype virus was iden-
tified for the first time in the Americas in Brazil in 201455. Subse-
quently, this virus has spread to multiple areas in that country. The 
index case was a traveller from Angola and the virus does not con-
tain the E1: A226V mutation, suggesting that it might have limited 
infectivity for Aedes albopictus.
Geographical expansion of the Asian genotype
The Asian genotype has spread throughout the Pacific in recent 
years. A small 2011 outbreak in New Caledonia began after two 
infected travellers returned from Indonesia where the virus had 
been circulating continuously for at least a decade56. The Asian 
genotype subsequently was noted during outbreaks in the following 
locations: Papua New Guinea (2012); Yap Island, Federated States 
of Micronesia (2013); Tonga, Samoa, American Samoa, Tokelau, 
French Polynesia (2014); and Kiribati and the Cook Islands 
(2015)44,47,57.
However, the most dramatic expansion occurred in the Americas 
where autochthonous transmission began on the Island of St. Martin 
in 201358. Genetic sequencing indicated that the virus was similar to 
chikungunya viruses recently identified from the Federated States 
of Micronesia, Philippines, and Indonesia59. Within a year, the virus 
spread to 26 islands and 14 mainland countries, resulting in more 
than 1 million reported cases. As of September 2015, 1.7 million 
cases and 240 deaths were reported from 45 of the 53 countries 
or territories reporting to the Pan American Health Organization 
(Figure 1). The true number of affected persons is undoubtedly 
Figure 1. Number of countries in the Americas with local chikungunya transmission and number of cases reported to the Pan American 
Health Organization, by month, December 2013–September 2015.
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substantially higher; since laboratory confirmation is completed 
in only a fraction of cases, infected individuals often do not seek 
medical care, and reporting may be incomplete. For example, Cuba 
has not reported any cases, yet infected travellers have returned to 
the United States from that country. While activity in many island 
countries in the Caribbean has decreased or stopped, transmission 
continues in most mainland countries.
In 2014, a total of 2788 cases were reported among travellers 
returning to the United States, nearly all from the Caribbean and 
Latin America. Despite this large influx, only 11 instances of auto-
chthonous transmission have been identified in the contiguous 
United States, all in Florida60.
Future outlook
Tropical areas
The continuing anthropogenic factors promoting the emergence 
and spread of chikungunya and other Aedes aegypti-borne diseases 
suggest that the current global epidemic will continue to spread to 
previously unaffected areas for some time. However, as the out-
break continues, herd immunity in humans will eventually curtail 
the scope and frequency of these outbreaks since humans are the 
virus’s only significant vertebrate host in urban settings and life-
long immunity follows infection. The level of herd immunity 
required to stop outbreaks is unknown and likely varies according 
to local underlying transmission dynamics, such as human popu-
lation size and mosquito abundance. Studies demonstrated that 
upwards of 60% of the population became infected during some 
outbreaks48, after which outbreaks ceased or were greatly reduced. 
One or two transmission seasons seem to be sufficient to curtail 
transmission activity in small, isolated populations such as islands, 
as has occurred in smaller Pacific Islands recently and now appears 
to be occurring in some Caribbean islands. At the other extreme, 
outbreaks in India, with its large and dispersed population, have 
moved from place to place now for nearly a decade, as they had in 
the early 1960s and 1970s. However, even in India, the reduction in 
susceptible populations had been apparently sufficient to prevent 
another large outbreak for 32 years.
In the Americas, several critical questions remain. As mentioned 
previously, the eventual duration and extent of epidemic activity is 
unknown, but will likely vary geographically. It is also unknown 
whether a sylvatic cycle will develop, enabling viral persistence 
without human-to-human transmission. The current outbreak’s 
substantial geographical reach and incidence make enduring syl-
vatic transmission a likely possibility if a mechanism exists for it 
to do so. Another question is to what extent the ECSA genotype 
introduced in Brazil will spread, which has important implications 
discussed later.
Subtropical and temperate areas
The potential for large chikungunya virus outbreaks on the fringes 
of the Aedes aegypti distribution, such as the southern United 
States, seems limited given our experiences with dengue61. Hun-
dreds of dengue-infected travellers entering the contiguous United 
States are reported each year62, but Aedes aegypti-vectored dengue 
outbreaks have been relatively infrequent, focal and self-limited. 
One exception was a dengue outbreak spanning two years and 
involving several hundred persons in Key West, Florida, the most 
southern point in the contiguous United States63. However, most 
dengue outbreaks have occurred in Texas when large outbreaks in 
northern Mexico spilled over into towns along the border. Investiga-
tions in Texas showed that sociological conditions that limit contact 
with the indoor-biting Aedes aegypti mosquito, such as the use of 
air conditioning, greatly limited transmission despite the presence 
of abundant Aedes aegypti populations63–66. Dengue outbreaks have 
not occurred in areas with Aedes albopictus but without Aedes 
aegypti in the contiguous United States.
So far, it appears that chikungunya virus is following a similar pat-
tern to dengue in subtropical and temperate areas of the United 
States. The thousands of infected returning travellers have produced 
only a handful of identified autochthonous transmission cases 
and no outbreaks. This dynamic could change, however, if large 
chikungunya outbreaks in northern Mexico spill over into border 
towns, as has occurred for dengue.
Of some concern, Aedes albopictus is endemic in much of the 
southern and eastern United States67 and laboratory experiments 
show that Aedes albopictus mosquitoes collected throughout the 
Americas are generally competent to transmit the Asian genotype 
chikungunya virus68,69. Nevertheless, to date the Italian outbreak of 
2007 is the only documented subtropical outbreak vectored solely 
by Aedes albopictus and this involved the ECSA virus with the 
E1: A226V mutation54. The ECSA genotype now circulating in 
Brazil may be less competent for transmission by Aedes albopictus 
mosquitoes than ECSA strains circulating in the Old World, as it 
does not possess the E1: A226V mutation, but it could prove prob-
lematic if the virus acquires mutations that increase vector compe-
tence and is introduced to subtropical and temperate areas endemic 
for Aedes albopictus.
Options for control
Historically, control of mosquito-transmitted viruses has relied 
heavily upon efforts aimed at reducing mosquito populations. These 
control activities focus on eliminating mosquito larval habitat and 
adulticiding. However, because Aedes aegypti and Aedes albopictus 
mosquitoes are container-breeding species that will lay eggs in 
nearly any water habitat, larval control efforts are a challenging, 
if not impossible, task70. Control efforts aimed at reducing adult 
mosquito populations also fail, because truck-based or aerial pes-
ticide applications do not reach many adults, which rest and bite 
indoors. Indoor residual pesticide spraying might be effective, but 
is impractical in large urban areas. In addition, the threshold Aedes 
aegypti population levels required to stop chikungunya transmis-
sion are unknown, but are likely quite low. Ominously, Singapore, a 
country with perhaps the most effective Aedes aegypti control pro-
gram globally, has experienced large chikungunya outbreaks vec-
tored by both Aedes aegypti and Aedes albopictus71,72. Several new 
Aedes aegypti control approaches are under development, but none 
are currently ready for widespread use73–75.
An alternative control option is the development of a chikungunya 
vaccine. Several platform options have been explored ranging from 
virus-like particles, live attenuated variants, virus-vectored prod-
ucts, subunit vaccines, DNA vaccines, or inactivated products76. 
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At least nine distinct options have been examined in pre-clinical 
research with most demonstrating the potential for protection in 
animal model systems. Only three have been tested in clinical trials: 
a live attenuated product developed by scientists at the Walter Reed 
Army Institute of Research (WRAIR) in the 1980s and 1990s77,78, a 
virus-like particles product developed recently at the National Insti-
tutes of Health79, and a measles-vectored product expressing the 
chikungunya virus structural genes80. While all appear to be prom-
ising candidates, the likelihood of a product reaching a commercial 
market are slim, due to the unpredictable nature of chikungunya 
virus outbreaks, the challenges associated with performing efficacy 
trials, and the uncertainty of revenue generating capacity. However, 
despite the challenges, a vaccine is one of the best options for pre-
venting further outbreaks.
Concluding remarks
Urbanization, human travel, viral adaption, lack of effective con-
trol measures, and spread of new vectors likely have contributed to 
recent re-emergence of chikungunya. The current global outbreak, 
unprecedented in its size and geographical scope, is comprised of 
many smaller outbreaks that extend from place to place via human 
movement, and continue unabated until sufficient herd immunity in 
local human populations develops, or changes in other conditions, 
such as weather, inhibit further transmission. In smaller, island 
populations only one or two transmission seasons seem sufficient 
to greatly curtail or eliminate transmission; whereas, in larger 
populations such as India, transmission may extend beyond a dec-
ade. Like many other mosquito-borne diseases, it is very difficult to 
predict if and when a chikungunya outbreak will occur in any given 
location. Another uncertainty is the risk of epidemics in subtropi-
cal and temperate regions of the world where Aedes albopictus is a 
potential vector. The Italian outbreak demonstrated the possibility 
of such outbreaks, but to date outbreaks have yet to materialize in 
the United States, despite thousands of imported cases. While new 
chikungunya vaccines seem an attractive control possibility, many 
obstacles exist for their eventual commercialization. The dramatic 
spread of the dengue, chikungunya, and Zika viruses in recent years 
highlights the urgent need to identify scalable and cost-effective 
Aedes aegypti control options.
Disclaimer
The findings and conclusions in this report are those of the author(s) 
and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention.
Competing interests
The authors declare that they have no competing interests.
Grant information
The author(s) declared that no grants were involved in supporting 
this work.
References F1000 recommended
Page 5 of 8
F1000Research 2016, 5(F1000 Faculty Rev):82 Last updated: 15 FEB 2016
37. Halstead SB, Udomsakdi S, Scanlon JE, et al.: Dengue and chikungunya virus 
infection in man in Thailand, 1962–1964. V. Epidemiologic observations outside 
Bangkok. Am J Trop Med Hyg. 1969; 18(6): 1022–33. 
PubMed Abstract 
38. Myers RM, Carey DE: Concurrent isolation from patient of two arboviruses, 
Chikungunya and dengue type 2. Science. 1967; 157(3794): 1307–8. 
PubMed Abstract | Publisher Full Text 
39. Padbidri VS, Gnaneswar TT: Epidemiological investigations of chikungunya 
epidemic at Barsi, Maharashtra state, India. J Hyg Epidemiol Microbiol Immunol. 
1979; 23(4): 445–51. 
PubMed Abstract 
40. Lahariya C, Pradhan SK: Emergence of chikungunya virus in Indian 
subcontinent after 32 years: A review. J Vector Borne Dis. 2006; 43(4): 151–60. 
PubMed Abstract 
41. Bhatt S, Gething PW, Brady OJ, et al.: The global distribution and burden of 
dengue. Nature. 2013; 496(7446): 504–7. 
PubMed Abstract | Publisher Full Text | Free Full Text 
42. Liang G, Gao X, Gould EA: Factors responsible for the emergence of 
arboviruses; strategies, challenges and limitations for their control. Emerg 
Microbes Infect. 2015; 4(3): e18. 
PubMed Abstract | Publisher Full Text | Free Full Text 
43. Kyle JL, Harris E: Global spread and persistence of dengue. Annu Rev Microbiol. 
2008; 62: 71–92. 
PubMed Abstract | Publisher Full Text 
44. Roth A, Mercier A, Lepers C, et al.: Concurrent outbreaks of dengue, chikungunya 
and Zika virus infections - an unprecedented epidemic wave of mosquito-
borne viruses in the Pacific 2012-2014. Euro Surveill. 2014; 19(41): pii: 20929. 
PubMed Abstract | Publisher Full Text 
45. Musso D, Nilles EJ, Cao-Lormeau VM: Rapid spread of emerging Zika virus in 
the Pacific area. Clin Microbiol Infect. 2014; 20(10): O595–6. 
PubMed Abstract | Publisher Full Text 
46. Musso D: Zika Virus Transmission from French Polynesia to Brazil. Emerging 
Infect Dis. 2015; 21(10): 1887. 
PubMed Abstract | Publisher Full Text | Free Full Text 
47. Musso D, Cao-Lormeau VM, Gubler DJ: Zika virus: following the path of dengue 
and chikungunya? Lancet. 2015; 386(9990): 243–4. 
PubMed Abstract | Publisher Full Text 
48. Sergon K, Yahaya AA, Brown J, et al.: Seroprevalence of Chikungunya virus 
infection on Grande Comore Island, union of the Comoros, 2005. Am J Trop 
Med Hyg. 2007; 76(6): 1189–93. 
PubMed Abstract 
49. Kariuki Njenga M, Nderitu L, Ledermann JP, et al.: Tracking epidemic 
Chikungunya virus into the Indian Ocean from East Africa. J Gen Virol. 2008; 
89(Pt 11): 2754–60. 
PubMed Abstract | Publisher Full Text | Free Full Text 
50.  Renault P, Solet JL, Sissoko D, et al.: A major epidemic of chikungunya 
virus infection on Reunion Island, France, 2005-2006. Am J Trop Med Hyg. 2007; 
77(4): 727–31. 
PubMed Abstract | F1000 Recommendation 
51.  Lambrechts L: Quantitative genetics of Aedes aegypti vector competence 
for dengue viruses: towards a new paradigm? Trends Parasitol. 2011; 27(3): 111–4. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
52.  Tsetsarkin KA, Vanlandingham DL, McGee CE, et al.: A single mutation in 
chikungunya virus affects vector specificity and epidemic potential. PLoS 
Pathog. 2007; 3(12): e201. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
53. Dash PK, Parida MM, Santhosh SR, et al.: East Central South African genotype 
as the causative agent in reemergence of Chikungunya outbreak in India. 
Vector Borne Zoonotic Dis. 2007; 7(4): 519–27. 
PubMed Abstract | Publisher Full Text 
54.  Rezza G, Nicoletti L, Angelini R, et al.: Infection with chikungunya virus in 
Italy: an outbreak in a temperate region. Lancet. 2007; 370(9602): 1840–6. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
55.  Teixeira MG, Andrade AM, Costa Mda C, et al.: East/Central/South African 
genotype chikungunya virus, Brazil, 2014. Emerging Infect Dis. 2015; 21(5): 
906–7. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
56. Cao-Lormeau VM, Musso D: Emerging arboviruses in the Pacific. Lancet. 2014; 
384(9954): 1571–2. 
PubMed Abstract | Publisher Full Text 
57. Nhan TX, Musso D: The burden of chikungunya in the Pacific. Clin Microbiol 
Infect. 2015; 21(6): e47–8. 
PubMed Abstract | Publisher Full Text 
58.  Leparc-Goffart I, Nougairede A, Cassadou S, et al.: Chikungunya in the 
Americas. Lancet. 2014; 383(9916): 514. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
59. Lanciotti RS, Valadere AM: Transcontinental movement of Asian genotype 
chikungunya virus. Emerging Infect Dis. 2014; 20(8): 1400–2. 
PubMed Abstract | Publisher Full Text | Free Full Text 
15. Thiberville S, Boisson V, Gaudart J, et al.: Chikungunya fever: a clinical and 
virological investigation of outpatients on Reunion Island, South-West Indian 
Ocean. PLoS Negl Trop Dis. 2013; 7(1): e2004. 
PubMed Abstract | Publisher Full Text | Free Full Text 
16. Kumar NP, Suresh A, Vanamail P, et al.: Chikungunya virus outbreak in Kerala, 
India, 2007: a seroprevalence study. Mem Inst Oswaldo Cruz. 2011; 106(8): 
912–6. 
PubMed Abstract | Publisher Full Text 
17. Moro ML, Gagliotti C, Silvi G, et al.: Chikungunya virus in North-Eastern Italy: a 
seroprevalence survey. Am J Trop Med Hyg. 2010; 82(3): 508–11. 
PubMed Abstract | Publisher Full Text | Free Full Text 
18. Sissoko D, Moendandze A, Malvy D, et al.: Seroprevalence and risk factors of 
chikungunya virus infection in Mayotte, Indian Ocean, 2005-2006: a population-
based survey. PLoS One. 2008; 3(8): e3066. 
PubMed Abstract | Publisher Full Text | Free Full Text 
19. Sharp TM, Roth NM, Torres J, et al.: Chikungunya cases identified through 
passive surveillance and household investigations--Puerto Rico, May  
5-August 12, 2014. MMWR Morb Mortal Wkly Rep. 2014; 63(48): 1121–8. 
PubMed Abstract 
20. Yoon I, Alera MT, Lago CB, et al.: High rate of subclinical chikungunya virus 
infection and association of neutralizing antibody with protection in a 
prospective cohort in the Philippines. PLoS Negl Trop Dis. 2015; 9(5): e0003764. 
PubMed Abstract | Publisher Full Text | Free Full Text 
21. Weaver SC, Forrester NL: Chikungunya: Evolutionary history and recent 
epidemic spread. Antiviral Res. 2015; 120: 32–9. 
PubMed Abstract | Publisher Full Text 
22.  Volk SM, Chen R, Tsetsarkin KA, et al.: Genome-scale phylogenetic 
analyses of chikungunya virus reveal independent emergences of recent 
epidemics and various evolutionary rates. J Virol. 2010; 84(13): 6497–504. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
23.  Higgs S, Vanlandingham D: Chikungunya virus and its mosquito vectors. 
Vector Borne Zoonotic Dis. 2015; 15(4): 231–40. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
24. Diallo M, Thonnon J, Traore-Lamizana M, et al.: Vectors of Chikungunya virus in 
Senegal: current data and transmission cycles. Am J Trop Med Hyg. 1999; 60(2): 
281–6. 
PubMed Abstract 
25.  Reiter P: Oviposition, dispersal, and survival in Aedes aegypti: 
implications for the efficacy of control strategies. Vector Borne Zoonotic Dis. 
2007; 7(2): 261–73. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
26.  Chretien J, Anyamba A, Bedno SA, et al.: Drought-associated chikungunya 
emergence along coastal East Africa. Am J Trop Med Hyg. 2007; 76(3): 405–7. 
PubMed Abstract | F1000 Recommendation 
27.  Kraemer MU, Sinka ME, Duda KA, et al.: The global compendium of Aedes 
aegypti and Ae. albopictus occurrence. Sci Data. 2015; 2: 150035. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
28.  Kraemer MU, Sinka ME, Duda KA, et al.: The global distribution of the 
arbovirus vectors Aedes aegypti and Ae. albopictus. eLife. 2015; 4: e08347. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
29.  Paupy C, Delatte H, Bagny L, et al.: Aedes albopictus, an arbovirus vector: 
from the darkness to the light. Microbes Infect. 2009; 11(14–15): 1177–85. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
30.  Bonizzoni M, Gasperi G, Chen X, et al.: The invasive mosquito species 
Aedes albopictus: current knowledge and future perspectives. Trends Parasitol. 
2013; 29(9): 460–8. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
31. Savage HM, Aggarwal D, Apperson CS, et al.: Host choice and West Nile virus 
infection rates in blood-fed mosquitoes, including members of the Culex 
pipiens complex, from Memphis and Shelby County, Tennessee, 2002–2003. 
Vector Borne Zoonotic Dis. 2007; 7(3): 365–86. 
PubMed Abstract | Publisher Full Text | Free Full Text 
32. Ledermann JP, Guillaumot L, Yug L, et al.: Aedes hensilli as a potential vector of 
Chikungunya and Zika viruses. PLoS Negl Trop Dis. 2014; 8(10): e3188. 
PubMed Abstract | Publisher Full Text | Free Full Text 
33.  Halstead SB: Reappearance of chikungunya, formerly called dengue, in the 
Americas. Emerg Infect Dis. 2015; 21(4): 557–61. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
34. Carey DE: Chikungunya and dengue: a case of mistaken identity? J Hist Med 
Allied Sci. 1971; 26(3): 243–62. 
PubMed Abstract | Publisher Full Text 
35. Sabin AB: The dengue group of viruses and its family relationships. Bacteriol 
Rev. 1950; 14(3): 225–32. 
PubMed Abstract 
36. Halstead SB, Scanlon JE, Umpaivit P, et al.: Dengue and chikungunya virus 
infection in man in Thailand, 1962–1964. IV. Epidemiologic studies in the 
Bangkok metropolitan area. Am J Trop Med Hyg. 1969; 18(6): 997–1021. 
PubMed Abstract 
Page 6 of 8
F1000Research 2016, 5(F1000 Faculty Rev):82 Last updated: 15 FEB 2016
dynamics and dengue prevention. Curr Top Microbiol Immunol. 2010; 338: 
115–28. 
PubMed Abstract | Publisher Full Text 
71.  Leo YS, Chow AL, Tan LK, et al.: Chikungunya outbreak, Singapore, 2008. 
Emerging Infect Dis. 2009; 15(5): 836–7. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
72.  Oon LL, Ng LC: Chikungunya in Singapore - the Battle Continues. Ann Acad 
Med Singapore. 2014; 43(6): 325–7. 
PubMed Abstract | F1000 Recommendation 
73.  Carvalho DO, McKemey AR, Garziera L, et al.: Suppression of a Field 
Population of Aedes aegypti in Brazil by Sustained Release of Transgenic Male 
Mosquitoes. PLoS Negl Trop Dis. 2015; 9(7): e0003864. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
74.  Lambrechts L, Ferguson NM, Harris E, et al.: Assessing the epidemiological 
effect of wolbachia for dengue control. Lancet Infect Dis. 2015; 15(7): 862–6. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
75.  Iturbe-Ormaetxe I, Walker T, O’ Neill SL: Wolbachia and the biological 
control of mosquito-borne disease. EMBO Rep. 2011; 12(6): 508–18. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
76. Ahola T, Courderc T, Ng LF, et al.: Therapeutics and vaccines against 
chikungunya virus. Vector Borne Zoonotic Dis. 2015; 15(4): 250–7. 
PubMed Abstract | Publisher Full Text 
77.  Hoke CH Jr, Pace-Templeton J, Pittman P, et al.: US Military contributions  
to the global response to pandemic chikungunya. Vaccine. 2012; 30(47):  
6713–20.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
78. Levitt NH, Ramsburg HH, Hasty SE, et al.: Development of an attenuated strain 
of chikungunya virus for use in vaccine production. Vaccine. 1986; 4(3): 
157–62. 
PubMed Abstract | Publisher Full Text 
79.  Chang LJ, Dowd KA, Mendoza FH, et al.: Safety and tolerability of 
chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-
escalation trial. Lancet. 2014; 384(9959): 2046–52. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
80.  Ramsauer K, Schwameis M, Firbas C, et al.: Immunogenicity, safety, and 
tolerability of a recombinant measles-virus-based chikungunya vaccine: a 
randomised, double-blind, placebo-controlled, active-comparator, first-in-man 
trial. Lancet Infect Dis. 2015; 15(5): 519–27. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
60.  Kendrick K, Stanek D, Blackmore C, et al.: Notes from the field: Transmission 
of chikungunya virus in the continental United States--Florida, 2014. MMWR 
Morb Mortal Wkly Rep. 2014; 63(48): 1137. 
PubMed Abstract | F1000 Recommendation 
61. Eisen L, Moore CG: Aedes (Stegomyia) aegypti in the continental United States: 
a vector at the cool margin of its geographic range. J Med Entomol. 2013; 50(3): 
467–78. 
PubMed Abstract | Publisher Full Text 
62. Mohammed HP, Ramos MM, Rivera A, et al.: Travel-associated dengue 
infections in the United States, 1996 to 2005. J Travel Med. 2010; 17(1): 8–14. 
PubMed Abstract | Publisher Full Text 
63.  Radke EG, Gregory CJ, Kintziger KW, et al.: Dengue outbreak in Key West, 
Florida, USA, 2009. Emerging Infect Dis. 2012; 18(1): 135–7. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
64.  Brunkard JM, Robles López JL, Ramirez J, et al.: Dengue fever 
seroprevalence and risk factors, Texas-Mexico border, 2004. Emerging Infect 
Dis. 2007; 13(10): 1477–83. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
65.  Ramos MM, Mohammed H, Zielinski-Gutierrez E, et al.: Epidemic dengue and 
dengue hemorrhagic fever at the Texas-Mexico border: results of a household-
based seroepidemiologic survey, December 2005. Am J Trop Med Hyg. 2008; 
78(3): 364–9. 
PubMed Abstract | F1000 Recommendation 
66.  Reiter P, Lathrop S, Bunning M, et al.: Texas lifestyle limits transmission of 
dengue virus. Emerging Infect Dis. 2003; 9(1): 86–9. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
67. Benedict MQ, Levine RS, Hawley WA, et al.: Spread of the tiger: global risk of 
invasion by the mosquito Aedes albopictus. Vector Borne Zoonotic Dis. 2007; 
7(1): 76–85. 
PubMed Abstract | Publisher Full Text | Free Full Text 
68.  Vega-Rúa A, Zouache K, Girod R, et al.: High level of vector competence of 
Aedes aegypti and Aedes albopictus from ten American countries as a crucial 
factor in the spread of Chikungunya virus. J Virol. 2014; 88(11): 6294–306. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
69.  Reiskind MH, Pesko K, Westbrook CJ, et al.: Susceptibility of Florida mosquitoes 
to infection with chikungunya virus. Am J Trop Med Hyg. 2008; 78(3): 422–5. 
PubMed Abstract | Free Full Text | F1000 Recommendation
70. Scott TW, Morrison AC: Vector dynamics and transmission of dengue virus: 
implications for dengue surveillance and prevention strategies: vector 
Page 7 of 8





  Current Referee Status:
Editorial Note on the Review Process
 are commissioned from members of the prestigious  and are edited as aF1000 Faculty Reviews F1000 Faculty
service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees
provide input before publication and only the final, revised version is published. The referees who approved the
final version are listed with their names and affiliations but without their reports on earlier versions (any comments
will already have been addressed in the published version).
The referees who approved this article are:
Version 1
, Diagnostic Medicine and Pathobiology, Kansas State University, Manhattan, Kansas, USAStephen Higgs
 No competing interests were disclosed.Competing Interests:
, Bureau of Epidemiology, Florida State Department of Health, Tallahassee, Florida, USACarina Blackmore
 No competing interests were disclosed.Competing Interests:
Page 8 of 8
F1000Research 2016, 5(F1000 Faculty Rev):82 Last updated: 15 FEB 2016
